These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 2016469)

  • 1. Pharmacologic roles of heparin and glucocorticoids to prevent restenosis after coronary angioplasty.
    Berk BC; Gordon JB; Alexander RW
    J Am Coll Cardiol; 1991 May; 17(6 Suppl B):111B-117B. PubMed ID: 2016469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The paradigm of restenosis following percutaneous transluminal coronary angioplasty.
    Preisack MB; Karsch KR
    Eur Heart J; 1993 Nov; 14 Suppl I():187-92. PubMed ID: 8293774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale for use of glucocorticoids in modification of restenosis after percutaneous transluminal coronary angioplasty.
    Macdonald RG; Panush RS; Pepine CJ
    Am J Cardiol; 1987 Jul; 60(3):56B-60B. PubMed ID: 2956845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation.
    Karsch KR; Preisack MB; Baildon R; Eschenfelder V; Foley D; Garcia EJ; Kaltenbach M; Meisner C; Selbmann HK; Serruys PW; Shiu MF; Sujatta M; Bonan R
    J Am Coll Cardiol; 1996 Nov; 28(6):1437-43. PubMed ID: 8917255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathophysiology and pharmacological approaches for prevention of coronary artery restenosis following coronary artery balloon angioplasty and related procedures.
    Landzberg BR; Frishman WH; Lerrick K
    Prog Cardiovasc Dis; 1997; 39(4):361-98. PubMed ID: 9050821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restenosis after coronary balloon angioplasty.
    Lange RA; Flores ED; Hillis LD
    Annu Rev Med; 1991; 42():127-32. PubMed ID: 2035958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia.
    Liu MW; Roubin GS; King SB
    Circulation; 1989 Jun; 79(6):1374-87. PubMed ID: 2524293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coronary intimal proliferation after balloon injury and stenting in swine: an animal model of restenosis.
    Karas SP; Gravanis MB; Santoian EC; Robinson KA; Anderberg KA; King SB
    J Am Coll Cardiol; 1992 Aug; 20(2):467-74. PubMed ID: 1634687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Subcutaneous Heparin and Angioplasty Restenosis Prevention (SHARP) trial. Results of a multicenter randomized trial investigating the effects of high dose unfractionated heparin on angiographic restenosis and clinical outcome.
    Brack MJ; Ray S; Chauhan A; Fox J; Hubner PJ; Schofield P; Harley A; Gershlick AH
    J Am Coll Cardiol; 1995 Oct; 26(4):947-54. PubMed ID: 7560622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experimental and early clinical experience with reviparin-sodium for prevention of restenosis after percutaneous transluminal coronary angioplasty.
    Preisack MB; Karsch KR
    Blood Coagul Fibrinolysis; 1993 Dec; 4 Suppl 1():S55-8; discussion S59-60. PubMed ID: 8180331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of restenosis with antioxidants: mechanisms and implications.
    Tardif JC; Grégoire J; L'Allier PL
    Am J Cardiovasc Drugs; 2002; 2(5):323-34. PubMed ID: 14727962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colchicine and antineoplastic therapy for the prevention of restenosis after percutaneous coronary interventions.
    Muller DW; Ellis SG; Topol EJ
    J Am Coll Cardiol; 1991 May; 17(6 Suppl B):126B-131B. PubMed ID: 2016470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of recombinant hirudin (CGP 39,393/TMREVASC) in the prevention of restenosis after percutaneous transluminal coronary angioplasty. Rationale and design of the HELVETICA trial, a multicentre randomized double blind heparin controlled study.
    Herrman JP; Simon R; Umans VA; Peerboom PF; Keane D; Rijnierse JJ; Bach D; Kobi P; Kerry R; Close P
    Eur Heart J; 1995 Nov; 16 Suppl L():56-62. PubMed ID: 8869020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restenosis after percutaneous transluminal coronary angioplasty: have we been aiming at the wrong target?
    Currier JW; Faxon DP
    J Am Coll Cardiol; 1995 Feb; 25(2):516-20. PubMed ID: 7829808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restenosis following placement of an intracoronary heparin treated tantulum stent in the hyperlipidemic miniature swine model.
    Jenkins JS; Webel R; Laughlin MH; Rowland SM; Yoklavich MF; Amann JF; Branson K; Myers PR
    J Invasive Cardiol; 1995; 7(6):173-82. PubMed ID: 10155102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Restenosis after coronary angioplasty: its pathogenesis and prevention].
    Marzocchi A; Marrozzini C; Piovaccari G; Fattori R; Castriota F; D'Anniballe G; Branzi A; Magnani B
    Cardiologia; 1991 Dec; 36(12 Suppl 1):309-20. PubMed ID: 1841786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First clinical experience with low molecular weight heparin LU 47311 (reviparin) for prevention of restenosis after percutaneous transluminal coronary angioplasty.
    Schmid KM; Preisack M; Voelker W; Sujatta M; Karsch KR
    Semin Thromb Hemost; 1993; 19 Suppl 1():155-9. PubMed ID: 8395719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Restenosis after coronary angioplasty.
    Anderson HV; Vignale SJ; Benedict CR; Willerson JT
    J Interv Cardiol; 1993 Sep; 6(3):187-202. PubMed ID: 10151016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cascade model for restenosis. A special case of atherosclerosis progression.
    Libby P; Schwartz D; Brogi E; Tanaka H; Clinton SK
    Circulation; 1992 Dec; 86(6 Suppl):III47-52. PubMed ID: 1424051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The in-vitro effect of antineoplastic agents on proliferative activity and cytoskeletal components of plaque-derived smooth-muscle cells from human coronary arteries.
    Voisard R; Dartsch PC; Seitzer U; Hannekum A; Roth D; Kochs M; Hombach V
    Coron Artery Dis; 1993 Oct; 4(10):935-42. PubMed ID: 8269201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.